ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa.
Mercè Grau-Pérez, Cristina Ciudad, Alejandro Molina-Leyva, Antonio Martorell, Eva Vilarrasa, Sofía Haselgruber, José Carlos Pascual, Fernando Alfageme, Irene Albert, Juan Garcias-Ladaria, Francisco Javier Melgosa, Raquel Rivera, Minia Campos, Gemma Ochando, Ramón García-Ruiz
{"title":"ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa.","authors":"Mercè Grau-Pérez, Cristina Ciudad, Alejandro Molina-Leyva, Antonio Martorell, Eva Vilarrasa, Sofía Haselgruber, José Carlos Pascual, Fernando Alfageme, Irene Albert, Juan Garcias-Ladaria, Francisco Javier Melgosa, Raquel Rivera, Minia Campos, Gemma Ochando, Ramón García-Ruiz","doi":"10.1159/000546647","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic disease that causes painful skin lumps and scarring in the skin. In an important number of patients, the disease starts in adolescence. Adalimumab was the first biologic drug approved in adolescents with HS, yet approval was done on a model-based extrapolation from other diseases. Data regarding the effectiveness and safety of adalimumab in HS in this age group is lacking. Our objective was to describe the effectiveness and safety of adalimumab in adolescents with moderate-to-severe HS.</p><p><strong>Methods: </strong>Retrospective multicenter case series. HS units across Spain were invited to participate, including all patients starting adalimumab in adolescence. Demographic, clinical, and treatment-related characteristics were retrieved. Effectiveness was measured as the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at 6 months. Safety was assessed by means of quantification and description of side effects over time.</p><p><strong>Results: </strong>A total of 65 patients from 9 HS units were included. Mean age at adalimumab start was 15.5 years. A total of 76.9% of patients achieved HiSCR at 6 months. Side effects were observed in 7 patients, 3 of them requiring drug discontinuation, with full recovery. The adult dosage (80 mg every other week [EOW]/40 mg every week) was more frequently used. The median drug survival time for adalimumab was 5.6 years (25th percentile: 2.9 years), and the recommended adolescent dosage (40 mg EOW) was associated with a need for intensification (p < 0.001). The main limitations of the study are the lack of a comparison group and the retrospective design.</p><p><strong>Conclusion: </strong>Adalimumab showed a similar safety profile in adolescents with moderate-to-severe HS as in adults, with better effectiveness data.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-7"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503423/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546647","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Hidradenitis suppurativa (HS) is a chronic disease that causes painful skin lumps and scarring in the skin. In an important number of patients, the disease starts in adolescence. Adalimumab was the first biologic drug approved in adolescents with HS, yet approval was done on a model-based extrapolation from other diseases. Data regarding the effectiveness and safety of adalimumab in HS in this age group is lacking. Our objective was to describe the effectiveness and safety of adalimumab in adolescents with moderate-to-severe HS.
Methods: Retrospective multicenter case series. HS units across Spain were invited to participate, including all patients starting adalimumab in adolescence. Demographic, clinical, and treatment-related characteristics were retrieved. Effectiveness was measured as the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at 6 months. Safety was assessed by means of quantification and description of side effects over time.
Results: A total of 65 patients from 9 HS units were included. Mean age at adalimumab start was 15.5 years. A total of 76.9% of patients achieved HiSCR at 6 months. Side effects were observed in 7 patients, 3 of them requiring drug discontinuation, with full recovery. The adult dosage (80 mg every other week [EOW]/40 mg every week) was more frequently used. The median drug survival time for adalimumab was 5.6 years (25th percentile: 2.9 years), and the recommended adolescent dosage (40 mg EOW) was associated with a need for intensification (p < 0.001). The main limitations of the study are the lack of a comparison group and the retrospective design.
Conclusion: Adalimumab showed a similar safety profile in adolescents with moderate-to-severe HS as in adults, with better effectiveness data.
期刊介绍：
Published since 1893, ''Dermatology'' provides a worldwide survey of clinical and investigative dermatology. Original papers report clinical and laboratory findings. In order to inform readers of the implications of recent research, editorials and reviews prepared by invited, internationally recognized scientists are regularly featured. In addition to original papers, the journal publishes rapid communications, short communications, and letters to ''Dermatology''. ''Dermatology'' answers the complete information needs of practitioners concerned with progress in research related to skin, clinical dermatology and therapy. The journal enjoys a high scientific reputation with a continually increasing impact factor and an equally high circulation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
